>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

  • CHGG +16%, DBD +12.5%, WH +8.9%, THC +8.5%, FANG +8%, NSP +7.7%, AER +7.6%, ACGL +7.5%, OHI +7.5%, RMBS +7.3%, LMNX +7%, TREX +6.5%, XPO +6.4%, ALSN +6.1%, NS +6.1%, HTGC +6%, PE +5.7%, ATI +5.4%, O +5.3%, USFD +5.2%, APTV +5%, REGN +4.8%, MPC +4.6%, TOT +4.4%, VAR +4.3%, JKHY +4.3%, CAR +4.1%, AGCO +4%, TDG +3.7%, LHX +2.8%, VRNS +2.7%, MOS +2.5%, HSIC +2.5%, CORT +2.4%, GPI +2.4%, LGIH +2.4%, EVER +2.1%, USCR +2.1%, GLT +2%, SWKS +1.9%, VNOM +1.9%, BWXT +1.8%, ICHR +1.7%, CRUS +1.7%, ACM +1.7%, LEG +1.3%

M&A news:

  • PTLA +130.9% ( to be acquired by Alexion (ALXN) for $18/share in cash)

Other news:

  • TGTX +33.7% (announces "positive" top-line results from the global UNITY-CLL Phase 3 trial evaluating the combination of umbralisib plus ublituximab (U2) compared to obinutuzumab plus chlorambucil in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia)
  • ADVM +22.4% (reports "positive" interim data from Cohorts 1-3 of OPTIC Phase 1 trial of ADVM-022 in wet AMD)
  • AKBA +18.4% (announces "positive" top-line results fromm global Phase 3 programs for vadadustat)
  • CEMI +14.8% (attains CE Marking for its DPP COVID-19 System)
  • GNMK +11.2% (names new CEO, increases full year outlook)
  • ITI +11.1% (sells Agriculture and Weather Analytics segment to DTN)
  • AVID +8% (renews cloud collaboration agreement with Microsoft)
  • EXPR +7.7% (provides details on store reopening plans)\
  • BNTX +4.8% (Pfizer and BioNTech SE doses first patients in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19)
  • QSR +4.1% (Pershing Square discloses 9.6% active stake; intends to engage with mgmt, board)
  • SBUX +3.4% (expects 90% of stores will likely be reopened in June, citing CNBC)
  • WBA +2.9% (AmerisourceBergen reportedly exploring deal for WBA's pharma wholesaling unit, according to Reuters)
  • PFE +1.8% (Pfizer and BioNTech SE doses first patients in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19)
  • ABBV +1% (receives Health Canada approval for the combination of VENCLEXTA with obinutuzumab for patients with previously untreated chronic lymphocytic leukemia)

Analyst comments:

  • CUTR +12.4% (upgraded to Buy from Hold at Stifel)
  • BCRX +8.7% (upgraded to Overweight from Equal Weight at Barclays)
  • HOG +2.8% (upgraded to Buy from Hold at Argus)
  • TWOU +2.4% (upgraded to Buy from Hold at Berenberg)